The Phase 3 ZIRCON study assessed the efficacy of 89Zr-DFO-girentuximab PET/CT in detecting ccRCC in IDRM pts. The study showed that 89Zr-DFO-girentuximab PET/CT is safe and effective for identifying and characterizing IDRMs. The detection of renal masses (RM) poses a significant challenge as current diagnostic tools such as CT, MRI, and biopsy have […]...
AUA 2023
Coverage of American Urological Association Annual Meeting
Apr 28
-May 01, 2023